Список литературы к Главe 2

1. Hallek M., Cheson B.D., Catovsky D., Caligaris­Cappio F., Dighiero G., Dohner H. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760.

2. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. Vol. 48, N 1. P. 198–206.

3. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia // Blood. 1975. Vol. 46, N 2. P. 219–234.

4. Baliakas P., Mattsson M., Stamatopoulos K., Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? // J. Intern. Med. 2016. Vol. 279, N 4. P. 347–357.

5. Gunnarsson R., Mansouri L., Rosenquist R. Exploring the genetic landscape in chronic lymphocytic leukemia using high­resolution technologies // Leuk. Lymphoma. 2013. Vol. 54, N 8. P. 1583–1590.

6. Caspersson T., Zech L., Johansson C., Modest E.J. Identification of human chromosomes by DNA­binding fluorescent agents // Chromosoma. 1970. Vol. 30, N 2. P. 215–227.

7. Goodwin S., McPherson J.D., McCombie W.R. Coming of age: ten years of next­generation sequencing technologies // Nat. Rev. Genet. 2016. Vol. 17, N 6. P. 333–351.

8. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N. et al. Whole­genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia // Nature. 2011. Vol. 475, N 7354. P. 101–105.

9. Quesada V., Conde L., Villamor N., Ordonez G.R., Jares P., Bassaganyas L. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia // Nat. Genet. 2011. Vol. 44, N 1. P. 47–52.

10. Wang L., Lawrence M.S., Wan Y., Stojanov P., Sougnez C., Stevenson K. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia // N. Engl. J. Med. 2011. Vol. 365, N 26. P. 2497–2506.

11. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation // J. Exp. Med. 2011. Vol. 208, N 7. P. 1389–1401.

12. Zech L., Mellstedt H. Chromosome 13 – a new marker for B­cell chronic lymphocytic leukemia // Hereditas. 1988. Vol. 108, N 1. P. 77–84.

13. Gahrton G., Robert K.H., Friberg K., Zech L., Bird A.G. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B­cell­mitogen stimulation // Blood. 1980. Vol. 56, N 4. P. 640–647.

14. Gahrton G., Robert K.H., Friberg K., Zech L., Bird A.G. Extra chromosome 12 in chronic lymphocytic leukaemia // Lancet. 1980. Vol. 1, N 8160. P. 146–147.

15. Hurley J.N., Fu S.M., Kunkel H.G., Chaganti R.S., German J. Chromosome abnormalities of leukaemic B lymphocytes in chronic lymphocytic leukaemia // Nature. 1980. Vol. 283, N 5742. P. 76–78.

16. Juliusson G., Oscier D.G., Fitchett M., Ross F.M., Stockdill G., Mackie M.J. et al. Prognostic subgroups in B­cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities // N. Engl. J. Med. 1990. Vol. 323, N 11. P. 720–724.

17. Haferlach C., Bacher U. Cytogenetic methods in chronic lymphocytic leukemia // Methods Mol. Biol. 2011. Vol. 730. P. 119–130.

18. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L. et al. Genomic aberrations and survival in chronic lymphocytic leukemia // N. Engl. J. Med. 2000. Vol. 343, N 26. P. 1910–1916.

19. Gunnarsson R., Mansouri L., Isaksson A., Goransson H., Cahill N., Jansson M. et al. Array­based genomic screening at diagnosis and during follow­up in chronic lymphocytic leukemia // Haematologica. 2011. Vol. 96, N 8. P. 1161–1169.

20. Haferlach C., Dicker F., Schnittger S., Kern W., Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping // Leukemia. 2007. Vol. 21, N 12. P. 2442–2451.

22. Mabuchi H., Fujii H., Calin G., Alder H., Negrini M., Rassenti L. et al. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candid ate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B­cell chronic lymphocytic leukemia // Cancer Res. 2001. Vol. 61, N 7. P. 2870–2877.

23. Migliazza A., Bosch F., Komatsu H., Cayanis E., Martinotti S., Toniato E. et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B­cell chronic lymphocytic leukemia // Blood. 2001. Vol. 97, N 7. P. 2098–2104.

24. Hammarsund M., Corcoran M.M., Wilson W., Zhu C., Einhorn S., Sangfelt O. et al. Characterization of a novel B­CLL candidate gene­DLEU7­located in the 13q14 tumor suppressor locus // FEBS Lett. 2004. Vol. 556, N 1–3. P. 75–80.

25. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E. et al. Frequent deletions and down­regulation of micro­RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 2002. Vol. 99, N 24. P. 15 524–15 529.

26. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M. et al. miR­15 and miR­16 induce apoptosis by targeting BCL2 // Proc. Natl Acad. Sci. USA. 2005. Vol. 102, N 39. P. 13 944–13 949.

27. Klein U., Lia M., Crespo M., Siegel R., Shen Q., Mo T. et al. The DLEU2/miR­15a/16­1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia // Cancer Cell. 2010. Vol. 17, N 1. P. 28–40.

28. Stilgenbauer S., Winkler D., Ott G., Schaffner C., Leupolt E., Bentz M. et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma // Blood. 1999. Vol. 94, N 9. P. 3262–3264.

29. Blakemore S.J., Clifford R., Parker H., Antoniou P., Stec­Dziedzic E., Larrayoz M. et al. Clinical significance of TP53, BIRC3, ATM and MAPK­ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial // Leukemia. 2020. Vol. 34, N 7. P. 1760–1774.

30. Rose­Zerilli M.J., Forster J., Parker H., Parker A., Rodriguez A.E., Chaplin T. et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q­deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial // Haematologica. 2014. Vol. 99, N 4. P. 736–742.

31. Schaffner C., Stilgenbauer S., Rappold G.A., Dohner H., Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B­cell chronic lymphocytic leukemia // Blood. 1999. Vol. 94, N 2. P. 748–753.

32. Skowronska A., Parker A., Ahmed G., Oldreive C., Davis Z., Richards S. et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial // J. Clin. Oncol. 2012. Vol. 30, N 36. P. 4524–4532.

33. Sutton L.A., Ljungstrom V., Mansouri L., Young E., Cortese D., Navrkalova V. et al. Targeted next­generation sequencing in chronic lymphocytic leukemia: a high­throughput yet tailored approach will facilitate implementation in a clinical setting // Haematologica. 2015. Vol. 100, N 3. P. 370–376.

34. Austen B., Powell J.E., Alvi A., Edwards I., Hooper L., Starczynski J. et al. Mutations in the ATM gene lead to impaired overall and treatment­free survival that is independent of IGVH mutation status in patients with B­CLL // Blood. 2005. Vol. 106, N 9. P. 3175–3182.

35. Dohner H., Stilgenbauer S., James M.R., Benner A., Weilguni T., Bentz M. et al. 11q deletions identify a new subset of B­cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis // Blood. 1997. Vol. 89, N 7. P. 2516–2522.

36. Hallek M., Fischer K., Fingerle­Rowson G., Fink A.M., Busch R., Mayer J. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial // Lancet. 2010. Vol. 376, N 9747. P. 1164–1174.

37. Tsimberidou A.M., Tam C., Abruzzo L.V., O’Brien S., Wierda W.G., Lerner S. et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia // Cancer. 2009. Vol. 115, N 2. P. 373–380.

38. Brieghel C., da Cunha­Bang C., Yde C.W., Schmidt A.Y., Kinalis S., Nadeu F. et al. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome // Clin. Cancer Res. 2020. Vol. 26, N 6. P. 1507–1515.

39. Mansouri L., Sutton L.A., Ljungstrom V., Sorqvist E.F., Gunnarsson R., Smedby K.E. et al. Feasibility of targeted next­generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia // Leukemia. 2014. Vol. 28, N 3. P. 694–696.

40. Del Giudice I., Rossi D., Chiaretti S., Marinelli M., Tavolaro S., Gabrielli S. et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL // Haematologica. 2012. Vol. 97, N 3. P. 437–441.

41. Ibbotson R., Athanasiadou A., Sutton L.A., Davis Z., Gardiner A., Baliakas P. et al. Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG­positive variant // Leukemia. 2012. Vol. 26, N 1. P. 170–172.

42. Baliakas P., Puiggros A., Xochelli A., Sutton L.A., Nguyen­Khac F., Gardiner A. et al. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference // Haematologica. 2016. Vol. 101, N 7. P. e299–e302.

43. Campo E., Cymbalista F., Ghia P., Jager U., Pospisilova S., Rosenquist R. et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics // Haematologica. 2018. Vol. 103, N 12. P. 1956–1968.

44. Dicker F., Herholz H., Schnittger S., Nakao A., Patten N., Wu L. et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype // Leukemia. 2009. Vol. 23, N 1. P. 117–124.

45. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V. et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage // Blood. 2009. Vol. 114, N 26. P. 5307–5314.

46. Zenz T., Habe S., Denzel T., Mohr J., Winkler D., Buhler A. et al. Detailed analysis of p53 pathway defects in fludarabine­refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53mutation, p53­p21 dysfunction, and miR34a in a prospective clinical trial // Blood. 2009. Vol. 114, N 13. P. 2589–2597.

47. International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL­IPI): a meta­analysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790.

48. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2013. Vol. 369, N 1. P. 32–42.

49. Roberts A.W., Davids M.S., Pagel J.M., Kahl B.S., Puvvada S.D., Gerecitano J.F. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 311–322.

50. Byrd J.C., Harrington B., O’Brien S., Jones J.A., Schuh A., Devereux S. et al. Acalabrutinib (ACP­196) in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 323–332.